Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules

Clara Cesana, Anna Maria Nosari, Catherine Klersy, Sara Miqueleiz, Valentina Rossi, Paola Ferrando, Marina Valentini, Luciana Barbarano, Enrica Morra

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Objectives. We evaluated bacterial infections (Bis) in patients with multiple myeloma (MM) treated with two different schedules of vincristine-adriamycin-dexamethasone (VAD). Design and Methods. Ninety-seven patients were studied during 340 VAD cycles. VAD was given by either continuous intravenous infusion (CII) to hospitalized patients or rapid intravenous infusion (RII) to outpatients. The characteristics of patients and VAD schedules were retrospectively analyzed to detect correlations with the incidence of BI. Results. By analyzing each VAD cycle, we found that profound hypogammaglobulinemia (p=0.06) and posttreatment neutropenia (p=0.08) were associated with a trend for a higher risk of infection, while renal function impairment was significantly correlated with BI risk at both univariate (p

Original languageEnglish
Pages (from-to)1022-1028
Number of pages7
JournalHaematologica
Volume88
Issue number9
Publication statusPublished - Sep 1 2003

Keywords

  • Bacterial infection
  • Multiple myeloma
  • VAD

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules'. Together they form a unique fingerprint.

Cite this